July 31, 2020 04:25 AM EDTUpdated August 31, 05:43 PM
Financing

AlloVir rides IPO boom on first mar­ket day, soars af­ter bag­ging $276 mil­lion

Nicole DeFeudis

Editor

Mass­a­chu­setts-based AlloVir hit Wall Street Thurs­day, join­ing the ranks of drug mak­ers to strike big in the 2020 IPO boom.

The biotech’s 16.3 mil­lion shares …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

A service from the Financial Times